Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors

Advanced Breast Cancer Clinical Trial

Official title:

A Phase II Clinical Trial of the PARP Inhibitor Talazoparib in BRCA1 and BRCA2 Wild Type Patients With Advanced Triple Negative Breast Cancer and Homologous Recombination Deficiency or Advanced HER2 Negative Breast Cancer or Other Solid Tumors With a Mutation in Homologous Recombination Pathway Genes

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02401347
• Other study ID #: IRB-31913
• Secondary ID: NCI-2015-00036BR
• Status: Completed
• Phase: Phase 2
• Start date: August 2015
• Est. completion date: December 2022

Study information

• Verified date: February 2023
• Source: Stanford University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this single-arm phase 2 clinical trial is to evaluate the anti-cancer activity of Talazoparib (also known as BMN 673) in patients with advanced breast cancer with specific genetic or tumor genomic alterations. Patients with either triple-negative or HER2-negative breast cancer are eligible.

Description:

Talazoparib (BMN 673) is a novel, dual-mechanism PARP inhibitor that potently inhibits the PARP enzyme and effectively traps PARP on DNA. Talazoparib has shown promising single-agent anti-tumor efficacy in several BRCA1/2 mutation-associated advanced cancers. The efficacy of PARP inhibition in BRCA1/2 wild-type TNBC with homologous recombination (HR) defects and in breast tumors with mutations in other non-BRCA1/2 HR pathway genes is currently unknown. This phase 2 trial explores the activity of single agent talazoparib in BRCA1/2 wild-type BC patients using an optimal Simon two-stage design. Eligible subjects will be assigned to one of two parallel cohorts: 1) Cohort A: Subjects (n=29) with advanced TNBC with underlying HR defects as assessed by the HRD assay and, 2) Cohort B: Subjects (n=29) with advanced HER2-negative BC with a somatic or germline mutation in a non-BRCA1/2 HR pathway gene. Gene mutations of interest are: PTEN, PALB2, CHEK2, ATM, NBN, BARD1, BRIP1, RAD50, RAD51C, RAD51D, MRE11, ATR, Fanconi anemia complementation group of genes (FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCL).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 21
• Est. completion date: December 2022
• Est. primary completion date: December 23, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

INCLUSION CRITERIA:

• No deleterious germline BRCA1 or BRCA2 mutation based on full sequencing and comprehensive rearrangement testing at an external reference laboratory; patients with variants of unknown significance will be eligible
• Measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1
• Must have progressed on at least 1 prior chemotherapy regimen for the treatment of advanced breast cancer; there is no upper limit on the number of prior therapies
• If prior platinum agent (eg, carboplatin or cisplatin) has been administered, no evidence of progression, or within 8 weeks of stopping platinum treatment
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
• Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 2.5 x upper limit of normal (ULN); if liver function abnormalities are due to hepatic metastasis, then AST and ALT = 5 x ULN
• Total serum bilirubin = 1.5 x ULN (= 3 x ULN for Gilbert's syndrome)
• Calculated creatinine clearance = 30 mL/min or serum creatinine = 1.5 mg/dL
• Hemoglobin = 9.0 g/dL with last transfusion at least 14 days before day 1 of study drug
• Absolute neutrophil count (ANC) = 1500/mm^3
• Platelet count = 100,000/mm^3
• Able to take oral medications
• Willing and able to provide written, signed informed consent after the nature of the study has been explained, and prior to any research-related procedures
• Sexually active patients of childbearing potential must be willing to use an acceptable method of contraception such as an intrauterine device or double barrier contraception during treatment and for 30 days after the last dose of study drug
• Females of childbearing potential must have a negative serum pregnancy test at screening and be willing to have additional serum pregnancy tests during the study; females considered not of childbearing potential include those who have been in menopause at least 2 years, or had tubal ligation at least 1 year prior to screening, or who have had total hysterectomy
• Willing and able to comply with all study procedures
• COHORT A SPECIFIC ELIGIBILITY CRITERIA:
• Histologically-confirmed metastatic or recurrent triple-negative breast cancer (defined as estrogen receptor = 5%, progesterone receptor = 5%, HER2-negative via immunohistochemistry [IHC] or fluorescent in situ hybridization [FISH])
• An homologous recombination deficiency (HRD) score = 42 on the HRD Assay as assessed on a tumor biopsy sample; in the case that obtaining an adequate metastatic tumor biopsy is not possible, we will assess the HRD score from the primary breast tumor
• COHORT B SPECIFIC ELIGIBILITY CRITERIA:
• Histologically-confirmed metastatic or recurrent HER2-negative (via IHC or FISH) breast cancer or other histologically-confirmed metastatic solid tumor
• Deleterious germline or somatic mutation implicated in the homologous recombination (HR) pathway, excluding BRCA1 or BRCA2, based on germline multiplex gene testing or direct tumor next generation DNA sequencing. Genes of interest include: PTEN, PALB2, CHEK2, ATM, NBN, BARD1, BRIP1, RAD50, Rad51c, Rad51d, MRE11, ATR, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCL, plus other HR-related genes at the discretion of the primary investigators.

EXCLUSION CRITERIA:

• Any patient with a deleterious mutation in BRCA1 or BRCA2
• Hormone receptor positive and/or HER2 positive breast cancer (Cohort A only)
• HER2 positive breast cancer (Cohort B only)
• Prior treatment with a PARP inhibitor
• Non-measurable disease only
• Pregnant or nursing patients
• Any anti-cancer therapy within the past 21 days of the first day of treatment
• Brain or central nervous system (CNS) metastases
• Exception: Adequately treated brain metastases documented by baseline computed tomography (CT) or magnetic resonance imaging (MRI) scan that have not progressed since previous scans and do not require corticosteroids (except prednisone = 5 mg/day or equivalent) for management of CNS symptoms. A repeated CT or MRI following the identification of CNS metastases (obtained at least 2 weeks after definitive therapy) must document adequately treated brain metastases
• Subjects with leptomeningeal carcinomatosis are not permitted
• Other malignancy that is either active or for which patient has received treatment in the last five years excluding non-melanoma skin cancer and carcinoma in situ of the cervix
• Radiation therapy in the last 14 days
• Known to be human immunodeficiency virus positive
• Known active hepatitis C virus
• Known active hepatitis B virus
• Use of any investigational product or investigational medical device within 28 days before day 1 of study drug
• Major surgery requiring a prolonged hospitalization or recovery within 21 days before day 1 of study drug
• Concurrent disease or condition that would interfere with study participation or

safety, such as any of the following:

• Active, clinically significant infection either grade > 2 by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 or requiring the use of parenteral anti-microbial agents within 7 days before day 1 of study drug
• Clinically significant bleeding diathesis or coagulopathy, including known platelet function disorders
• Known hypersensitivity to any of the components of BMN 673

Related Conditions & MeSH terms

• Advanced Breast Cancer
• Breast Neoplasms
• HER2/Neu Negative
• Triple Negative Breast Neoplasms
• Triple-Negative Breast Cancer

Intervention

Drug:
• Talazoparib Tosylate
Participants receive Talazoparib tosylate at 1 mg by mouth daily.

Locations

Country	Name	City	State
United States	Stanford Medicine at Stanford University	Stanford	California

Sponsors (3)

Lead Sponsor	Collaborator
Melinda Telli	BioMarin Pharmaceutical, Pfizer

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective Response (OR)	Objective response (OR) is a common measure of benefit. OR is defined as the number of participants who achieved complete response (CR) or partial clinical (PR), per the Response Evaluation Criteria in Solid Tumors (RECIST) Criteria (v1.1). RECIST Criteria are assessed by physical measurement; magnetic resonance imaging (MRI); computed tomography (CT), positron emission tomography (PET)-CT; and/or X-rays, as follows: CR = Disappearance of all target and non-target lesions; PR = =30% decrease in the sum of the long diameter of target lesions; OR = CR+PR; Stable disease (SD) = Small changes that do not meet any of the above criteria; Progressive disease (PD) = =20% increase in long diameter of target lesions, and/or the appearance of any new lesion(s) The outcome is expressed as the number of participants that achieved either CR or PR within 24 weeks of the start of treatment, a number without dispersion.	up to 24 weeks
Secondary	Clinical Benefit (CB)	Clinical benefit (CB) is a common measure of benefit. CB is defined as the number of participants who achieved complete response (CR); partial clinical (PR); or stable disease (SD), per the Response Evaluation Criteria in Solid Tumors (RECIST) Criteria (v1.1). RECIST Criteria are assessed by physical measurement; magnetic resonance imaging (MRI); computed tomography (CT), positron emission tomography (PET)-CT; and/or X-rays, as follows: CR = Disappearance of all target and non-target lesions; PR = =30% decrease in the sum of the long diameter of target lesions; SD = Small changes that do not meet any of the above criteria; CB = CR+PR+SD; Progressive disease (PD) = =20% increase in long diameter of target lesions, and/or the appearance of any new lesion(s) The outcome is expressed as the number of participants that achieved either CR, PR, or SD within 24 weeks of the start of treatment, a number without dispersion.	up to 24 weeks
Secondary	Progression-free Survival (PFS)	Progression-free survival (PFS) is a common measure of benefit. PFS means to remain alive with disease or tumor progression. Progression was defined per the Response Evaluation Criteria in Solid Tumors (RECIST) Criteria (v1.1) as any =20% increase in long diameter of the target lesions, and/or the appearance of any new lesion(s). PFS is expressed as the number of participants who remained alive without progression after 1 year, a number without dispersion.	1 year